All Updates

All Updates

icon
Filter
Partnerships
Inocras and Massive Bio partner for enhanced personalized care in cancer treatment
Clinical Trial Technology
Jun 3, 2024
This week:
Robinhood launches joint investment accounts
Retail Trading Infrastructure
Yesterday
Partnerships
eToro partners with London Stock Exchange to expand UK stock offerings
Retail Trading Infrastructure
Yesterday
Funding
StorMagic secures funding from Palatine Growth Credit Fund
Edge Computing
Yesterday
Funding
Archera raises USD 17 million in Series B funding for product development and recruitment
Cloud Optimization Tools
Yesterday
Funding
Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100
Precision Medicine
Yesterday
Partnerships
Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases
Precision Medicine
Yesterday
Product updates
USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products
Next-gen Satellites
Yesterday
Industry news
Sweden issues study on Gripen fighter jet’s satellite launch capability
Next-gen Satellites
Yesterday
Product updates
Regulation/policy
Terran Orbital receives certification for new manufacturing facility to begin production
Next-gen Satellites
Yesterday
Partnerships
Crisalion Mobility partners with Air Chateau for pre-order of eVTOL aircraft
Passenger eVTOL Aircraft
Yesterday
Clinical Trial Technology

Clinical Trial Technology

Jun 3, 2024

Inocras and Massive Bio partner for enhanced personalized care in cancer treatment

Partnerships

  • Inocras and Massive Bio have entered a partnership to improve personalized cancer treatment and care.

  • The collaboration involves employing Inocras's whole-genome sequencing (WGS) and bioinformatics expertise with Massive Bio's AI technology for clinical trial matching, which will permit cancer patients to be informed of prospective clinical trials that align with their genetic profile without the need for additional tests. Massive Bio is expected to enhance the scope of trial enrollment by reducing screen failures using its predictive analytics.

  • The alliance aims to increase the benefits of precision medicine for cancer patients and deliver tailored cancer care based on individual genetic profiles.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.